Contact Us
Drug Search Results
More Filters [+]

UCB-4594

Alternative Names: UCB-4594, UCB 4594, UCB4594
Latest Update: 2024-08-20
Latest Update Note: Clinical Trial Update

Product Description

UCB4594 is an antibody targeting the immune checkpoint, human leukocyte antigen G, also known as HLA-G. (Sourced from: https://www.ucb.com/stories-media/Press-Releases/article/Cancer-Research-UK-Signs-Multi-Project-Collaboration-With-UCB-To-Advance-Oncology-Antibody-Candidates)

Mechanisms of Action: HLA-G Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cancer Research UK
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for UCB-4594

Countries in Clinic: United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Breast Cancer|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CRUKD/24/001

P2

Recruiting

Ovarian Cancer|Colorectal Cancer|Gastrointestinal Cancer|Breast Cancer|Pancreatic Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Renal Cell Carcinoma|Esophageal Cancer|Cervical Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Stromal Tumors

2029-11-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions